20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Damora Therapeutics, Inc. (DMRA) operates in the BIOTECHNOLOGY industry and is headquartered in Waltham, United States with about 7 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, DMRA reported $0M in revenue and ($210M) in net income.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | — | — | — |
| Gross Profit | $0M | $0M | $0M | ($1M) | $0M | $0M | $0M | $0M | — |
| Gross Margin % | — | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($271M) | ($211M) | ($17M) | ($36M) | ($61M) | ($52M) | ($34M) | ($39M) | ($13M) |
| Operating Margin % | — | — | — | — | — | — | — | — | — |
| Net Income | ($263M) | ($210M) | ($21M) | ($38M) | ($62M) | ($52M) | ($35M) | ($37M) | ($16M) |
| Net Margin % | — | — | — | — | — | — | — | — | — |
| EBITDA | ($266M) | ($210M) | ($21M) | ($38M) | ($61M) | ($51M) | ($33M) | ($39M) | ($13M) |
| Earnings Per Share (EPS) | $-4.31 | $-153.95 | $-18.53 | $-36.08 | $-60.63 | $-51.22 | $-34.48 | $-35.88 | $-15.60 |
| Shares Outstanding (M) | 61M | 1M | 1M | 1M | 1M | 1M | 1M | 1M | 1M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($35M) | ($31M) | ($202M) | ($3M) | ($3M) | ($3M) | ($3M) | ($4M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($31M) | ($28M) | ($201M) | ($3M) | ($3M) | ($3M) | ($7M) | ($4M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($35M) | ($28M) | ($201M) | ($3M) | ($3M) | ($3M) | ($7M) | ($4M) |
| Earnings Per Share (EPS) | $-0.51 | $-0.81 | $-121.10 | $-2.36 | $-2.60 | $-3.00 | $-5.22 | $-3.39 |
| Shares Outstanding (M) | 61M | 34M | 2M | 1M | 1M | 1M | 1M | 1M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($45M) | ($7M) | ($19M) | ($37M) | ($43M) | ($52M) | ($38M) | ($19M) | ($14M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($45M) | ($7M) | ($19M) | ($37M) | ($43M) | ($53M) | ($38M) | ($19M) | ($14M) |
| FCF Margin % | — | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($22M) | ($21M) | $1M | ($3M) | ($2M) | ($2M) | ($5M) | ($4M) |
| Free Cash Flow (FCF) | ($22M) | ($21M) | $1M | ($3M) | ($2M) | ($2M) | ($5M) | ($4M) |
| FCF Margin % | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $544M | $261M | $17M | $38M | $73M | $122M | $172M | $57M | $35M |
| Cash & Cash Equivalents | $541M | $258M | $14M | $21M | $33M | $63M | $164M | $11M | $31M |
| Total Liabilities | $28M | $20M | $3M | $6M | $11M | $5M | $6M | $8M | $4M |
| Total Debt (Short + Long-Term) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Total Shareholders' Equity | $516M | $240M | $14M | $32M | $62M | $117M | $165M | $48M | $31M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive DMRA viewer.
About TickerBase · Data methodology & sources · Privacy · Terms